Mutual Funds & ETF's
Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
After XTANDI’s FDA Approval, Medivation Pulls Back
Stock Market News & Stocks to Watch from StraightStocks
Posted on November 16, 2012 at 08:13 AM EST
Investors who had long-term positions in Medivation Inc. (NASDAQ: MDVN) had an incredible 2012, which was sweetened by an early FDA approval for their flagship drug XTANDI (enzalutamide) in the treatment of prostate cancer post-chemotherapy.
Read More >>
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Bots go here